Steve E. Krognes Sells 3,339 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 3,339 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the transaction, the director now directly owns 25,757 shares of the company’s stock, valued at $536,003.17. The trade was a 11.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $21.25 on Friday. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33. The firm has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. The business’s 50-day simple moving average is $24.23 and its 200-day simple moving average is $24.86.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the business earned ($0.72) EPS. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Institutional Trading of Denali Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. CWM LLC lifted its stake in shares of Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares in the last quarter. Quest Partners LLC acquired a new position in Denali Therapeutics during the 3rd quarter worth approximately $73,000. Assetmark Inc. boosted its holdings in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after acquiring an additional 580 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after acquiring an additional 920 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Denali Therapeutics during the second quarter valued at approximately $194,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. HC Wainwright cut their price objective on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday. Robert W. Baird started coverage on Denali Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $31.00 price target for the company. Jefferies Financial Group raised their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $38.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.